Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience.

ABSTRACT:

Background

Upfront docetaxel or novel hormonal agents (NHA) such as abiraterone and enzalutamide have become the standard of care for metastatic hormone sensitive prostate cancer (mHSPC). We evaluated real-world management of patients treated with these agents at a single center.

Patients and methods

Patients with de novo mHSPC treated with upfront docetaxel or an NHA between January 2014 and April 2019 at Mount Sinai Health System were included. We evaluated time to next treatment (TTNT), PSA progression free survival (PFS) and overall survival (OS) after initial treatment with these drugs. Kaplan Meier method and multivariable Cox proportional hazards models were used for analysis. We additionally assessed the prognostic value of post-treatment PSA.

Results

We ident

SUBMITTER: Guin S 

PROVIDER: S-EPMC9390935 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature